Description
Ursodeoxycholic Acid 300 mg Tablets
Indications:
- Primary Biliary Cirrhosis (PBC)
- Primary Sclerosing Cholangitis (PSC)
- Intrahepatic Cholestasis of Pregnancy (ICP)
- Prevention and dissolution of cholesterol gallstones
Mechanism of Action:
- UDCA facilitates bile flow and protects hepatocytes, reducing elevated liver enzyme levels.
- Concentrates in bile to reduce biliary cholesterol by:
- Suppressing hepatic cholesterol synthesis and secretion
- Inhibiting intestinal absorption of cholesterol
- Decreases cholesterol saturation, leading to gradual gallstone dissolution.
Key Features:
- Micronized UDCA ensures improved absorption and enhanced bioavailability for better clinical outcomes.
- Delays progression of PBC, reducing the need for liver transplantation.
- In PSC patients, high-dose UDCA (25–30 mg/kg/day) improves liver function and Mayo risk scores.
- Safe in pregnancy: Improves itching and liver function in ICP without affecting fetoplacental estrogen production.
- Alternative to cholecystectomy in non-calcified gallstones.
- Effective in non-diabetic, non-cirrhotic Indian NAFLD as an alternative to Vitamin E.
- Well-tolerated with minimal side effects reported.
Dosage:
As directed by the physician.
Presentation:
Available as a Alu-Alu strip of 10 tablets:
HEPZU 300 mg Micronized
Storage:
Store in a cool, dry place.
Protect from light and moisture.
Reviews
There are no reviews yet.